CRISPR Therapeutics AG (CRSP)
CRISPR Therapeutics develops gene editing medicines, including CASGEVY, an approved therapy for sickle cell disease and beta thalassemia. It last closed at $40.15 on Nov 17, down 0.54% on the day. CRSP reports earnings on Thu, Feb 11, 2027. The average 12-month price target from 5 analysts is $74.80 (+86.3% from the last close), with a high of $90.00 and a low of $52.00. Analyst consensus is Buy, based on the latest ratings from 5 firms (3 buy, 2 hold, 0 sell). In the past 30 days there were 2 dark pool prints totaling $1.8M, the largest $1.1M.
Key Stats
Last 12 monthsNot reported for this period.
From CRSP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 2). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 5 analysts who set a price target on CRSP in the past 90 days. The average target is $74.80, with a high of $90.00 and a low of $52.00, compared with the last close of $40.15.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 4 | Citigroup | Target raised | Buy | $88 → $90 |
| Nov 4 | Wells Fargo | Maintained | Hold | $70 |
| Nov 3 | Needham | Reiterated | Buy | $82 |
| Oct 15 | UBS | Initiated | Hold | $52 |
| Aug 31 | Citizens | Reiterated | Buy | $80 |
Technical Analysis
The stock is 20% below its 20 day and 28% below its 50 day average. It is 31% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 29), oversold. The nearest support is the 52 week low at $39.80, and the nearest resistance the Pivot at $40.37.
| RSI (14) | 28.90 | Oversold below 30 | Oversold |
| MACD | -2.84 | Below its signal line | Bearish |
| Stochastic | 2.9 | Near the bottom of its range | Oversold |
| ADX (14) | 19.1 | No clear trend | |
| Williams %R | -97.8 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -168.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −19.7% | Change over 10 sessions | Bearish |
| ATR (14) | $2.56 | Typical daily range, 6.4% of price |
| RSI (14) | 36.57 | Weak, oversold below 30 | Neutral |
| MACD | -2.01 | Below its signal line | Bearish |
| Stochastic | 7.2 | Near the bottom of its range | Oversold |
| ADX (14) | 28.8 | Trending up | |
| Williams %R | -98.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -202.9 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −22.4% | Change over 10 sessions | Bearish |
| ATR (14) | $6.03 | Typical daily range, 15.0% of price |
What happened before
See how CRSP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How CRSP has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in CRSP in the last 90 days.
Dark Pool
30DCRSP Institutional Ownership
Full report →- ▲233 buying vs 201 selling
- ●Held by funds +0.1 pts
- ▼Funds holding -21
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 504 | 525 | −4.0% |
| In funds' top 10 | 6 | 6 | 0.0% |
| Held by funds | 79.0% | 78.8% | +0.1 pts |
| New / increased | 57 / 176 | 74 / 156 | +1.3% |
| Reduced / sold out | 136 / 65 | 141 / 47 | +6.9% |
| Put/call ratio | 0.68 | 0.75 | −9.1% |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CRSP is in one of them and how their past CRSP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CRSP in an article yet. Here's the latest on the wider market.
CRSP Congress Trades
All congress trades →| Person | Type | Amount | Traded | Filed | Delay |
|---|---|---|---|---|---|
| Robert KennedyExecutive branch | Sell | $1K – $15K | Apr 4, 2025 | May 17, 2025 | 43 d |
| Ashley MoodyR · FL | Sell | $1K – $15K | Feb 24, 2025 | Mar 22, 2025 | 26 d |
| Tom SuozziD · NY | Sell | $50K – $100K | Sep 20, 2021 | Oct 5, 2021 | 15 d |
| Tom SuozziD · NY | Buy | $50K – $100K | Jun 3, 2021 | Sep 23, 2021 | 112 d |
| Marjorie Taylor GreeneR · GA | Buy | $1K – $15K | Jan 21, 2021 | Feb 19, 2021 | 29 d |
Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.
About CRISPR Therapeutics AG
CRISPR Therapeutics is a biopharmaceutical company based in Zug, Switzerland, that develops medicines using CRISPR gene editing technology. Its approved therapy, CASGEVY, is co-developed and co-commercialized with Vertex and treats eligible patients with sickle cell disease or beta thalassemia. The company's pipeline also includes gene editing treatments for liver diseases, siRNA medicines for cardiovascular and clotting conditions, cell therapies for autoimmune diseases and cancer, and a cell-based treatment for type 1 diabetes. Its medicines target patients with serious diseases, and partners include Vertex and Eli Lilly.
- Headquarters
- Zug
- Founded
- 2013
- Website
- crisprtx.com ↗







